Cover Image
市場調查報告書

血液相關的各種合作契約:契約條件・合意內容

Global Hematology Partnering 2010-2016: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 248068
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
血液相關的各種合作契約:契約條件・合意內容 Global Hematology Partnering 2010-2016: Deal trends, players and financials
出版日期: 2016年09月01日 內容資訊: 英文
簡介

本報告,調查分析血液相關的各種合作契約,彙整近年的各種契約動向、大型契約及大型醫藥品業者的契約概要、契約種類・開發階段・疾病區分・技術區分別指南等,由下列摘要形式闡述。

報告摘要

第1章 簡介

第2章 血液相關的各種契約動向

  • 簡介
  • 過去數年的血液相關合作
  • 大型藥廠的契約活動
  • 對血液相關事業不積極的大型藥廠
  • 血液相關合作:契約種類別
  • 血液相關合作:產業部門別
  • 血液相關合作:開發階段別
  • 血液相關合作:技術類型別
  • 血液相關合作:症狀別
  • 平均契約期間

第3章 主要契約

  • 簡介
  • 主要契約:交易額別
  • 大型藥廠相關的主要契約

第4章 大型藥廠的契約

  • 簡介
  • 本資料的使用方法
  • 合作企業的檔案資料

第5章 合作契約指南

  • 簡介
  • 契約種類別
    • 資產購買
    • 權利讓渡
    • 大型委外授權
    • 共同開發
    • 共同R&D
    • 委託服務
    • 共同促銷
    • 開發
    • 銷售
    • 股票購入
    • 評價
    • 授權
    • 訴訟
    • 製造
    • 材料移轉
    • 選項
    • 研究
    • 調停
    • 再授權
    • 供給
    • 技術移轉
    • 終止
  • 開發階段別
    • 藥物設計
    • 配方
    • 市售後
    • 第I階段
    • 第II階段
    • 第III階段
    • 前臨床
    • 申請
  • 技術類型別
    • 分析
    • 篩選
    • 生物學化合物
    • 生物材料
    • 血液製劑
    • 細胞治療
    • 臨床試驗
    • 裝置
    • 診斷
    • 藥物設計工具
    • 藥物傳遞
    • 實現技術
    • 機器
    • 設備
    • 基因體學
    • 產業用化學品
    • 奈米科技
    • 寡核甘酸
    • 孤兒藥
    • 包裝
    • 縮氨酸
    • 製程
    • 蛋白質體學
    • 放射線/化療
    • 重組DNA
    • 再生醫療
    • 研究服務
    • 研究用消耗品
    • RNA治療
    • 篩選
    • 小分子
    • 軟體工具
    • 幹細胞

第6章 血液相關契約:症狀別

  • 簡介
  • 症狀別契約
    • 血液學
    • 貧血
    • 鐵質缺乏症
    • 代用血液
    • 嗜中性白血球缺乏症
    • 血球增多症
    • 地中海貧血
    • 血小板缺乏症
    • 維他命K缺乏症
    • 溫偉伯氏病

第7章 合作機會

  • 線上合夥
  • 合作活動
  • 相關資料
  • 關於Wildwood Ventures

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2207

The ‘Global Hematology Partnering 2010-2016: Deal trends, players and financials report’ provides comprehensive understanding and unprecedented access to the hematology partnering deals and agreements entered into by the worlds leading healthcare companies

‘Global Hematology Partnering 2010 to 2016’ provides the full collection of Hematology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Hematology partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Hematology partnering agreement structure
  • Hematology partnering contract documents
  • Top Hematology deals by value
  • Most active Hematology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Hematology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Hematology deals.

The report presents financial deal terms values for Hematology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Hematology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Hematology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Hematology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Hematology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Hematology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Hematology partnering deals by specific Hematology target announced since 2010. The chapter is organized by specific Hematology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Hematology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Hematology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Hematology technologies and products.

Report scope

‘Global Hematology Partnering 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Hematology trends and structure of deals entered into by leading companies worldwide.

‘Global Hematology Partnering 2010 to 2016’ includes:

  • Trends in Hematology dealmaking in the biopharma industry since 2010
  • Analysis of Hematology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Hematology deal contract documents
  • Comprehensive access to over 3500 Hematology deal records
  • The leading Hematology deals by value since 2010
  • Most active Hematology dealmakers since 2010

The report includes deals for the following indications: Agranulocytosis, Anemia, Haemolytic, Iron deficiency, Blood substitute, Disseminated intravascular coagulation (DIC), Hemophilia, Immune thrombocytopenic purpura, Neutropenia, Polycythemia, Thalassemia, Thrombocytopenia, Vitamin K Deficiency, Von-Willebrand disease, plus other hematological indications.

In ‘Global Hematology Partnering 2010 to 2016’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Hematology Partnering 2010-2016’ report provides comprehensive access to available deals and contract documents for over 1,000 hematology deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Hematology Partnering 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Hematology deal trends since 2010
  • Access Hematology deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Hematology partner companies
  • Comprehensive access to over 750 links to actual Hematology deals entered into by the world's biopharma companies
  • Indepth review of Hematology deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Hematology opportunities
  • Uncover companies actively partnering Hematology opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Hematology dealmaking

  • 2.1. Introduction
  • 2.2. Hematology partnering over the years
  • 2.3. Hematology partnering by deal type
  • 2.4. Hematology partnering by industry sector
  • 2.5. Hematology partnering by stage of development
  • 2.6. Hematology partnering by technology type
  • 2.7. Hematology partnering by therapeutic indication

Chapter 3 -Financial deal terms for Hematology partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Hematology partnering
  • 3.3. Hematology partnering headline values
  • 3.4. Hematology deal upfront payments
  • 3.5. Hematology deal milestone payments
  • 3.6. Hematology royalty rates

Chapter 4 - Leading Hematology deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Hematology partnering
  • 4.3. List of most active dealmakers in Hematology
  • 4.4. Top Hematology deals by value

Chapter 5 - Hematology contract document directory

  • 5.1. Introduction
  • 5.2. Hematology partnering deals where contract document available

Chapter 6 - Hematology dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Hematology therapeutic target

Appendices

  • Appendix 1 - Directory of Hematology deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Hematology deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Hematology deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Hematology deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Hematology partnering since 2010
  • Figure 2: Hematology partnering by deal type since 2010
  • Figure 3: Hematology partnering by industry sector since 2010
  • Figure 4: Hematology partnering by stage of development since 2010
  • Figure 5: Hematology partnering by technology type since 2010
  • Figure 6: Hematology partnering by indication since 2010
  • Figure 7: Hematology deals with a headline value
  • Figure 8: Hematology deals with upfront payment values
  • Figure 9: Hematology deals with milestone payment
  • Figure 10: Hematology deals with royalty rates
  • Figure 11: Active Hematology dealmaking activity- 2010 to 2016
  • Figure 12: Top Hematology deals by value since 2010
Back to Top